{'fraction_non_alphanumeric': 0.04013157894736842, 'fraction_numerical': 0.03684210526315789, 'mean_word_length': 4.988188976377953, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Randomized, comparative study to evaluate efficacy and safety of doxazosin versus nitrendipine in the treatment of mild to moderate hypertension].

Doxazosin, an alfa-1 adrenoceptor antagonist, was compared with nitrendipine, a calcium antagonist, to evaluate their efficacy and safety in 61 patients with mild to moderate hypertension. 31 patients were assigned randomly to receive 1-16 mg of doxazosin and 30 patients were assigned to 10-20 mg of nitrendipine during 14 weeks (10 weeks of titration and 4 weeks of maintenance). Mean final dose was 6.1 mg for doxazosin and 15.6 mg for nitrendipine. Both treatments reduced supine and standing diastolic and systolic blood pressure (p < 0.01 for all comparisons). 22 patients in the doxazosin group (78.6%) and 18 in the nitrendipine group (78.3%) were considered therapy successes. There were not clinically significant changes in laboratory tests for both groups. Global assessment of adverse events was similar for both treatments (46.7% for doxazosin and 44.8% for nitrendipine), although patients treated with nitrendipine presented facial rush (20%) against none of the doxazosin group (p < 0.05). Withdrawals due to adverse events were higher in the nitrendipine group than in the doxazosin one (20.7% versus 6.7%, p = 0.14). The results of this study confirms that both antihypertensives reduced blood pressure in patients with mild to moderate hypertension. Furthermore, doxazosin treatment demonstrates a fewer number of withdrawals caused by adverse events.